Vioxx firm may settle with drug claimants
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The US pharmaceutical giant which manufactured the scandal-hit arthritis pain drug Vioxx has signalled that it may consider settling some lawsuits alleging harm from the tablets.
Merck, which was told to pay out $253m (£141m) after a jury in Texas found the drug had contributed to a man's death and that the firm had been negligent, indicated it may soften its stand and settle some of the other related cases out of court. It had previously said it would fight each of the thousands of Vioxx lawsuits one by one.
Kent Jarrell, a spokesman for Merck's legal team, said: "For a relatively small set of cases that involve patients who used Vioxx for over 18 months, we will take a close look." The comment echoed published comments earlier in the day by Merck's general counsel.
The drug is known to have been taken by more than 20 million people worldwide and almost 500,000 Britons have used it. Merck withdrew the popular pain and arthritis drug in September after it was shown to double the risk of heart attack and stroke among patients who took it for 18 months or longer.
Last week a court found Merck to be negligent in the death of a 59-year-old triathlete, Robert Ernst, who died from heart arrhythmia after taking the drug for no more than eight months. It was the first of 4,200 similar lawsuits worldwide.
Merck has vowed to appeal against the verdict and use the lessons learnt from that defeat to better defend itself in the second Vioxx trial, due to begin on 12 September in Atlantic City, the casino resort town 125 miles from the drug-maker's headquarters in Whitehouse Station, New Jersey. The company's lawyers have asked the court to delay the start for 45 days to allow a "torrent" of bad publicity from the first trial to die down.
About 2,100 Vioxx cases have been filed in the US. MSB Solicitors in Liverpool, representing affected Britons, is preparing to submit clients' medical records to US doctors, saying thousands of Britons could sue.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments